Navigation Links
ImMAGE Biotherapeutics Closes Out 2016 in France as a YEi Laureate
Date:2/16/2017

PHILADELPHIA, Feb. 16, 2017 /PRNewswire-USNewswire/ -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing the power of the immune system to find a better treatment for triple negative breast cancer (TNBC), announced today their completion of the YEi Start in France program.

The YEi Start in France program is an accelerator designed to help entrepreneurs grow their business in France and Europe.  ImMAGE Biotherapeutics was one of eight American companies selected to complete an intensive one week immersion in France in December that provided introductions to an extensive customized business network and connections to the best resources in Europe.

"It was an honor to be included among the eight YEi laureates in 2016," said ImMAGE Biotherapeutics President and COO Mahesh Narayanan. "During the course of the program, I had the opportunity to meet with influential companies and investors, including potential partners and mentors that can support our potential expansion overseas."

Narayanan visited a number of research and cancer centers that could be potential clinical sites for ImMAGE in the future.  Among the centers were Gustave Roussy, a major cancer center in Europe that specializes in breast cancer, especially with early stage clinical trials; EFS, an immunotherapy research center; and CGFL, a research institute that specializes in using imaging to study biodistribution of drugs.

In addition, Narayanan met with companies that have potential to collaborate with ImMAGE, including Onxeo, an orphan oncology drug development company with four drugs currently in the pipeline, and Oncodesign, a preclinical contract research organization.

ImMAGE plans to start collaborating with many of these institutions over the next 12 months. Gustave Roussy and CHUV/CGFL are potential clinical sites for Europe. Oncodesign is a potential collaborator for the non-GLP efficacy studies, while Onxeo might be an early partner for future development of various candidates.

About ImMAGE Biotherapeutics
ImMAGE Biotherapeutics Corp. (OTCMKTS: IMMG) was founded in 2015 to harness the power of the human immune system to treat cancer. The company, which has a presence in the Washington, DC and Philadelphia regions, is developing multiple viable candidates to treat triple-negative breast cancer (TNBC) and has progressed from in-vitro trials to animal testing. The immunotherapy market is expected to grow to $9 billion by 2022 and may be used in up to 60% of cases of advanced cancer. Learn more at www.immagebio.com

CONTACT: Zhi Mou, 1-866-692-2939

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immage-biotherapeutics-closes-out-2016-in-france-as-a-yei-laureate-300408909.html


'/>"/>
SOURCE ImMAGE Biotherapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. ImMAGE Biotherapeutics to Present at the 9th Annual Biotech Showcase Conference
2. ImMAGE Biotherapeutics Announces Positive Results from Animal Studies
3. ImMAGE Biotherapeutics Announces Positive Results from In Vitro Trials
4. How These Biotech Stocks are Faring? -- Agenus, Tokai Pharma, Eleven Biotherapeutics, and Rexahn Pharma
5. Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans
6. Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics
7. Biotech Stocks on Investors Radar -- Eleven Biotherapeutics, Illumina, Sangamo Biosciences, and CytRx
8. Biotech Stocks on Investors Radar -- Northwest Biotherapeutics, ACADIA Pharma, Acorda Therapeutics, and Ultragenyx Pharma
9. Stealth BioTherapeutics To Present At 28th Annual Piper Jaffray Healthcare Conference
10. Stealth BioTherapeutics To Present At Stifel 2016 Healthcare Conference
11. Asterias Biotherapeutics Announces Treatment of First Spinal Cord Injury Patient with Maximum Dose of AST-OPC1 in SCiStar Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... CHAPEL, Fla. , June 28, 2017 ... help Universities boost their STEM education and research dollars. ... students with the latest fiber optic spectroscopy and photonics ... the program are: ... starting at 10% of equipment purchases used for the ...
(Date:6/28/2017)... CA (PRWEB) , ... June 28, 2017 , ... ... in the international market with three research projects accepted for presentation at the ... (ESHRE) . Nearly 10,000 participants – including some of the world’s top thought ...
(Date:6/28/2017)... ... 2017 , ... Supplies of the critical medical isotope molybdenum-99 (Mo-99) are secure ... Nuclear Medicine and Molecular Imaging (SNMMI) 2017 annual meeting in Denver, Colorado in June. ... to 40 million nuclear medicine procedures worldwide every year. (1) , Sally Schwarz, ...
(Date:6/27/2017)... ... June 27, 2017 , ... Brain State Technologies, a ... campaign on June 15th to fund production of the new B2v2 wearable brainwave ... Kickstarter goal by more than 150% in a little over a week. , ...
Breaking Biology Technology:
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed ... received the prestigious international IAIR Award for the most innovative high security ... ... Maldives Immigration Controller General, ... picture on the right) have received the IAIR award for the "Most ...
(Date:3/23/2017)... 2017 The report "Gesture Recognition and Touchless Sensing Market ... - Global Forecast to 2022", published by MarketsandMarkets, the market is expected to ... between 2017 and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
Breaking Biology News(10 mins):